# What This Bill Does

This bill makes it easier for pharmacies and hospitals to quickly create custom medications when patients urgently need them but approved drugs aren't available. Think of it like this: if a hospital patient needs a specific medication right away and the standard version isn't in stock or doesn't exist, a pharmacist can now compound (mix together) a custom version without jumping through as many regulatory hoops.

The bill creates two main pathways for urgent medication compounding. First, when a doctor certifies that they've tried but failed to get an FDA-approved drug or one made by a specialized compounding facility, a pharmacist can make a small batch of the needed medication for immediate hospital use. Second, when there's a nationwide drug shortage listed by the FDA or the American Society of Hospital Pharmacists, pharmacists can compound replacement medications without waiting for individual patient prescriptions. In both cases, the compounded drugs must be clearly labeled as urgent-use only and marked for hospital administration, not for patients to take home.

The bill includes safety guardrails to protect patients. Pharmacists must track which patients actually receive these compounded medications and report back within a week, ensuring accountability. They also have to follow proper labeling standards and report any bad reactions to the FDA's safety monitoring system within 15 days. This means the government can still keep tabs on whether these emergency medications are working safely, even though they're being made faster than usual.

Essentially, this bill speeds up access to critical medications during emergencies while maintaining oversight to catch any safety problems. It mainly affects hospital patients and healthcare providers, making it possible to treat urgent medical situations that would otherwise be delayed by standard drug approval timelines.

Patient Access to Urgent-Use Pharmacy Compounding Act of 2021

Griffith, H. Morgan

Patient Access to Urgent-Use Pharmacy Compounding Act of 2021 This bill relaxes certain requirements for compounding drugs that are facing shortages. Drug compounding is the process of mixing or otherwise altering drugs to create a medication. Currently, the Food and Drug Administration (FDA) allows for drug compounding subject to certain requirements. Generally a licensed pharmacist or physician not registered with the FDA may only compound drugs in limited quantities for prescriptions for a specific individual patient. On the other hand, an FDA-registered outsourcing facility may compound drugs in bulk for use in medical facilities but is subject to additional requirements. This bill allows a compounder not registered with the FDA to compound drugs in limited quantities for urgent medical need not involving a specific patient if, among other things, (1) the prescriber certifies that they are unable to obtain, despite reasonable attempts, certain related drugs with the same active ingredient and route of administration; (2) the compounded drug meets certain labeling requirements, including an indication that the compounded drug is provided only for urgent administration to a patient; and (3) the compounder requests and maintains certain records about patients receiving the compounded drug. Furthermore, a restriction against an unregistered compounder regularly compounding (or compounding inordinate amounts of) what is essentially a copy of a commercially available drug shall not apply if the drug is on a shortage list maintained by the FDA or the American Society of Hospital Pharmacists.